GoAI
Get started
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc.

PYXS

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$3.08

−$0.04 · -1.28%

Aug 21, 3:55 PM ET

PYXS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

36

Expensive

Momentum

65

Gaining

Sentiment

72

Bullish

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Thomas Civik
Listed since
Oct 8, 2021
Employees
56

Market position

Volume
682.28K
0.67× average
Average volume
1.01M
Average daily volume
Market cap
195.13M USD
Beta
1.32
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
74.72M USD
P/E (TTM)
-2.18×
P/B (TTM)
17.23×
P/S (TTM)
17.68×
EV / EBITDA
-1.01×
Earnings yield
-111.41%
Free cash flow yield
-88.87%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.76%
Operating margin
-834.44%
Net margin
-803.83%
Return on equity
-149.08%
Return on assets
-87.00%
Return on invested capital
-117.12%

Financial health

Debt / equity
1.56×
Current ratio
3.41×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends168%-115%-397%-680%Gross margin, FY2024: 97.06%Gross margin, FY2025: 82.77%Operating margin, FY2024: -554.07%Operating margin, FY2025: -609.18%Net margin, FY2024: -478.95%Net margin, FY2025: -574.55%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 97.06%. Gross margin FY2025 82.77%. Operating margin FY2024 -554.07%. Operating margin FY2025 -609.18%. Net margin FY2024 -478.95%. Net margin FY2025 -574.55%.

Income trends

Revenue

13.86M USD-14.17%

Operating income

−84.42M USD+5.63%

Net income

−79.62M USD-2.96%
Income trends across reported periods30.11M USD−25.74M USD−81.59M USD−137.44M USDRevenue, FY2024: 16.15M USDRevenue, FY2025: 13.86M USDOperating income, FY2021: −69.72M USDOperating income, FY2022: −123.48M USDOperating income, FY2023: −82.2M USDOperating income, FY2024: −89.46M USDOperating income, FY2025: −84.42M USDNet income, FY2021: −75.98M USDNet income, FY2022: −120.72M USDNet income, FY2023: −73.79M USDNet income, FY2024: −77.33M USDNet income, FY2025: −79.62M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 16.15M USD. Revenue FY2025 13.86M USD. Operating income FY2021 −69.72M USD. Operating income FY2022 −123.48M USD. Operating income FY2023 −82.2M USD. Operating income FY2024 −89.46M USD. Operating income FY2025 −84.42M USD. Net income FY2021 −75.98M USD. Net income FY2022 −120.72M USD. Net income FY2023 −73.79M USD. Net income FY2024 −77.33M USD. Net income FY2025 −79.62M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue13.86M USD16.15M USD———
Cost of goods sold2.39M USD475K USD———
Gross profit11.47M USD15.67M USD———
Research and development73.7M USD58.75M USD49.59M USD86.13M USD51.05M USD
Selling, general, and administrative22.19M USD25.42M USD32.61M USD37.35M USD18.66M USD
Operating expenses95.89M USD105.13M USD82.2M USD123.48M USD69.72M USD
Interest income3.61M USD7.04M USD6.63M USD2.76M USD23K USD
Depreciation and amortization4.51M USD2.98M USD1.93M USD709K USD647K USD
Operating income−84.42M USD−89.46M USD−82.2M USD−123.48M USD−69.72M USD
Net income−79.62M USD−77.33M USD−73.79M USD−120.72M USD−75.98M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+3.03%
11 comparable reports
Latest EPS result
-0.4
Estimate -0.35 · Miss by 14.29%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.23-0.36-0.49-0.62Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -0.58, estimate -0.33, surprise -75.76%, Miss. Q2 2025, reported May 15, 2025: actual -0.35, estimate -0.29, surprise -20.69%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.3, estimate -0.36, surprise +16.67%, Beat. Q4 2025, reported Nov 3, 2025: actual -0.35, estimate -0.36, surprise +2.78%, Beat. Q1 2026, reported Mar 23, 2026: actual -0.29, estimate -0.35, surprise +17.14%, Beat. Q2 2026, reported May 14, 2026: actual -0.37, estimate -0.35, surprise -5.71%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.4, estimate -0.35, surprise -14.29%, Miss. Q4 2026, reported Nov 2, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates17.44M11.63M5.82M16.52KQ1 '24BeatQ2 '24BeatQ1 '25EstimateQ3 '25No estimateQ1 '26BeatQ2 '26EstimateQ3 '26Estimate
Q1 2024, reported Mar 21, 2024: actual 3.42M USD, estimate 170K USD, surprise +1911.76%, Beat. Q2 2024, reported May 14, 2024: actual 16.15M USD, estimate 4.12M USD, surprise +291.89%, Beat. Q1 2025, reported Mar 18, 2025: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 2.82M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 23, 2026: actual 11.04M USD, estimate 125K USD, surprise +8730.40%, Beat. Q2 2026, reported May 14, 2026: actual —, estimate 19.44K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual —, estimate 33.33K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.50

111.04% upside
Past 12 months12-month forecastHigh $7.00Average $6.50Low $6.00

Rating distribution

10 ratings
Strong buy00%
Buy880%
Hold220%
Sell00%
Strong sell00%

PYXS news

globenewswire.com

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO…

Read source
defenseworld.net

Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)

GenSight Biologics (OTCMKTS:GSGTF - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on…

Read source
globenewswire.com

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap

Read source

PYXS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PYXS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.27M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.59M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.23M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
526.52K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
32.02K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
11.46K
Weight
0.01%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
6.66K
Weight
0.01%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%

Continue in GoAI

Research PYXS

research.disclaimer